The BET Protein Inhibitor JQ1 Decreases Hypoxia and Improves the Therapeutic Benefit of Anti-PD-1 in a High-Risk Neuroblastoma Mouse Model

The BET Protein Inhibitor JQ1 Decreases Hypoxia and Improves the Therapeutic Benefit of Anti-PD-1 in a High-Risk Neuroblastoma Mouse Model

Anti-programmed death 1 (PD-1) is a revolutionary treatment for many cancers. The response to anti-PD-1 relies on several properties of tumor and immune cells, including the expression of PD-L1 and PD-1. Despite the impressive clinical benefit achieved with anti-PD-1 in several cancers in adults, th...

Full description

Bibliographic Details
Main Authors: Delphine Sauvage, Manon Bosseler, Elodie Viry, Georgia Kanli, Anais Oudin, Guy Berchem, Olivier Keunen, Bassam Janji
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Cells
Subjects:
neuroblastoma
immune checkpoint inhibitors
PD-1/PD-L1
immunotherapy
hypoxia
epigenetic drugs
Online Access:https://www.mdpi.com/2073-4409/11/18/2783

Internet

https://www.mdpi.com/2073-4409/11/18/2783

Similar Items